Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inter-lot Consistency of DTcP Vaccine in Infants
NCT06857370Phase 3Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis (3-component) in diphtheria, Tetanus and pertussis (3 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Geometric Mean Concentration of serum anti-PT, FHA, PRN, DT, and TT antibodies. Started Mar 2025; status: active, not recruiting.
02
Drugs
diphtheria + tetanus + acellular pertussis (3-component)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT06857370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857370.